+54%

est. 2Y upside i

HealthcareSeries A

Introducing the industry's first Care Readiness Platform. Silna handles all prior authorizations, benefit checks and insurance monitoring upfront to make sure your patients are clear to receive care, and you have more capacity to provide it.

Rank

#1672

Sector

Healthcare IT

Est. Liquidity

~5Y

Data Quality

Data: Medium

Silna Health operates in a large and growing healthcare IT market, addressing the critical pain point of prior authorizations with a strong AI-powered platform.

Last updated: March 10, 2026

Bull (25%)+300%

Silna's proprietary AI and LLM technology achieves widespread adoption beyond specialty care, becoming the dominant pre-RCM platform. Strong regulatory tailwinds from new CMS rules accelerate growth, pushing revenue to over $150M by 2028 and justifying a $480M+ valuation at a premium multiple, well above the current estimated $120M.

Base (30%)+50%

Silna maintains its strong position within specialty healthcare, growing steadily but facing increasing competitive pressure from incumbents integrating similar AI solutions. Revenue reaches approximately $50M by 2028, leading to an acquisition at a $180M valuation, providing a moderate return for common shareholders after preferences.

Bear (45%)-80%

Major healthcare IT incumbents like ModMed or NextGen successfully integrate advanced AI for prior authorizations, commoditizing Silna's core offering. Growth stalls, and the company struggles to raise further capital, leading to a down round or distressed acquisition at a valuation below $50M, wiping out most common stock value given the $27M in liquidation preferences.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Investors hold $27M in liquidation preferences ahead of common stock. In an exit at or below the estimated $120M current valuation, common stock holders would see their returns significantly reduced or eliminated until the $27M preference is paid out.

Dilution Risk

high

As a Series A company, Silna will likely undergo multiple additional funding rounds over the next few years, which will dilute existing equity holders' ownership percentage.

Secondary Liquidity

none

There is no active secondary market for Silna's shares at this early stage, limiting opportunities for early liquidity.

Questions to Ask at the Interview

Strategic questions based on Silna's data — designed to show you've done your homework.

  • 1

    “Given Silna's strong competitive moat from proprietary AI and deep integrations, how does the company plan to maintain its advantage against major healthcare IT incumbents like ModMed, Tebra, and NextGen Healthcare, who have extensive resources to develop similar AI capabilities?”

  • 2

    “Silna has achieved a 98% first-pass acceptance rate with its Predictive Document Intelligence. What is the strategy for scaling this success beyond specialty healthcare providers and into broader healthcare settings to capture a larger share of the $254.2B SAM?”

  • 3

    “As a Series A company with $27M in total funding, how does Silna envision the path to a liquidity event for employees, and what are the company's plans for managing future dilution?”

Community

Valuation Sentiment

Our model estimates +54% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.